UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Natural history of chronic hepatitis B in Euro-Mediterranean and African Countries

Journal of hepatology, 2011-07, Vol.55 (1), p.183-191

Hadziyannis, Stephanos J

2011

Volltextzugriff (PDF)

Adding‐on versus switching‐to adefovir therapy in lamivudine‐resistant HBeAg‐negative chronic hepatitis B

Hepatology (Baltimore, Md.), 2007-02, Vol.45 (2), p.307-313

2007

Volltextzugriff (PDF)

Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B

Virology journal, 2022-01, Vol.19 (1), p.22-22, Article 22

2022

Volltextzugriff (PDF)

Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients

Hepatology (Baltimore, Md.), 2006-09, Vol.44 (3), p.694-702

2006

Volltextzugriff (PDF)

Predicting Outcomes of Patients With Chronic Hepatitis B Virus Infection Based on Quantification of the Hepatitis B Surface Antigen

Clinical gastroenterology and hepatology, 2016-10, Vol.14 (10), p.1499-1501

Hadziyannis, Stephanos J., MD

2016

Volltextzugriff (PDF)

Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir

Gastroenterology (New York, N.Y. 1943), 2012-09, Vol.143 (3), p.629-636.e1

2012

Volltextzugriff (PDF)

Milestones and perspectives in viral hepatitis B

Liver international, 2011-01, Vol.31 (s1), p.129-134

Hadziyannis, Stephanos J.

2011

Volltextzugriff (PDF)

Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B

The New England journal of medicine, 2003-02, Vol.348 (9), p.800-807

2003

Volltextzugriff (PDF)

Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels

Antiviral therapy, 2007, Vol.12 (1), p.73-82

2007

Volltextzugriff (PDF)

The Natural Course of Chronic Hepatitis B Virus Infection and Its Management

Advances in Pharmacology, 2013, Vol.67, p.247-291

2013

Volltextzugriff (PDF)

A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients

Gastroenterology (New York, N.Y. 1943), 2005-10, Vol.129 (4), p.1198-1209

2005

Volltextzugriff (PDF)

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

Hepatology (Baltimore, Md.), 2002-07, Vol.36 (1), p.219-226

2002

Volltextzugriff (PDF)

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection

Journal of hepatology, 2011-07, Vol.55 (1), p.69-75

2011

Volltextzugriff (PDF)

Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype

Journal of hepatology, 2013-12, Vol.59 (6), p.1153-1159

2013

Volltextzugriff (PDF)

Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis

European journal of gastroenterology & hepatology, 2008-01, Vol.20 (1), p.5-9

2008

Volltextzugriff (PDF)

Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years

Gastroenterology (New York, N.Y. 1943), 2006-12, Vol.131 (6), p.1743-1751

2006

Volltextzugriff (PDF)

Hepatitis B e antigen—negative chronic hepatitis B

Hepatology (Baltimore, Md.), 2001-10, Vol.34 (4), p.617-624

2001

Volltextzugriff (PDF)

Hepatitis B e Antigen-Negative Chronic Hepatitis B: Natural History and Treatment

Seminars in liver disease, 2006-05, Vol.26 (2), p.130-141

2006

Volltextzugriff (PDF)

Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dose

Annals of internal medicine, 2004-03, Vol.140 (5), p.346

Hadziyannis, Stephanos J.

2004

Volltextzugriff (PDF)

Efficacy and safety of peginterferon alfa‐2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

Hepatology (Baltimore, Md.), 2010-02, Vol.51 (2), p.388-397

2010

Volltextzugriff (PDF)

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy

Hepatology (Baltimore, Md.), 2006-05, Vol.43 (5), p.954-960

2006

Volltextzugriff (PDF)

Erratum to: “Natural history of chronic hepatitis B in Euro-Mediterranean and African Countries” [J Hepatol 2011;55:183–191]

Journal of hepatology, 2013-05, Vol.58 (5), p.1062-1062

Hadziyannis, Stephanos J

2013

Volltextzugriff (PDF)

Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel

Journal of hepatology, 2011-06, Vol.54 (6), p.1250-1262

2011

Volltextzugriff (PDF)

Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B

The New England journal of medicine, 2005-06, Vol.352 (26), p.2673-2681

2005

Volltextzugriff (PDF)

Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility

Expert review of gastroenterology & hepatology, 2014-02, Vol.8 (2), p.185-195

2014

Volltextzugriff (PDF)

1 – 25 von 148

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(139)
Mit Volltextzugriff
(118)

Publikationsform

Artikel
(147)
Reviews
(1)

Sprache

Englisch
(147)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(97)
Science & Technology
(95)
Life Sciences & Biomedicine
(94)
Gastroenterology & Hepatology
(75)
Biological And Medical Sciences
(62)
Medical Sciences
(59)
Male
(57)
Female
(52)
Adult
(47)
Middle Aged
(41)
Antiviral Agents - Therapeutic Use
(37)
Hepatitis B, Chronic - Drug Therapy
(34)
Infectious Diseases
(30)
Interferon-Alpha - Therapeutic Use
(27)
Human Viral Diseases
(26)
Viral Diseases
(26)
Viral Hepatitis
(26)
Aged
(24)
Recombinant Proteins
(22)
Gastroenterology. Liver. Pancreas. Abdomen
(20)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Natural history of chronic hepatitis B in Euro-Mediterranean and African Countries

Adding‐on versus switching‐to adefovir therapy in lamivudine‐resistant HBeAg‐negative chronic hepatitis B

Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B

Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients

Predicting Outcomes of Patients With Chronic Hepatitis B Virus Infection Based on Quantification of the Hepatitis B Surface Antigen

Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir

Milestones and perspectives in viral hepatitis B

Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B

Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels

The Natural Course of Chronic Hepatitis B Virus Infection and Its Management

A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection

Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype

Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis

Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years

Hepatitis B e antigen—negative chronic hepatitis B

Hepatitis B e Antigen-Negative Chronic Hepatitis B: Natural History and Treatment

Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dose

Efficacy and safety of peginterferon alfa‐2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy

Erratum to: “Natural history of chronic hepatitis B in Euro-Mediterranean and African Countries” [J Hepatol 2011;55:183–191]

Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel

Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B

Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility

Suchergebnisse filtern